You probably know someone whose memory has slipped more than it should.
Most of us think of Alzheimer's as a disease that strikes late, once the damage is done.
Scientists are now looking much earlier, at changes that start years before the first symptoms.
A drug called KCL-286 repaired DNA damage and calmed inflammation in mice with Alzheimer's-like disease. The findings come from researchers at King's College London, published in July 2026 in FEBS Open Bio.
Also read: A wireless brain implant just gave a third totally blind patient artificial vision
The twist is that KCL-286 was originally developed for spinal cord injury. It has already cleared Phase 1 human safety trials, which means the first step of drug testing in people, checking that the compound is tolerated, has been done.
DNA damage and inflammation
Most approved Alzheimer's drugs target the sticky amyloid plaques that build up in the brain. But two other problems appear much earlier. Brain cells pick up breaks in their DNA, and immune cells in the brain start a slow burn of inflammation.
A DNA double-strand break is the worst kind of damage a cell can get. Both strands of the DNA ladder snap at the same spot. If a brain cell cannot repair the break, it stops working properly, and over time it can die.
KCL-286 is a first-in-class drug. It switches on a protein called retinoic acid receptor-beta, part of the body's vitamin A system. Switching that protein on helps brain cells turn on their DNA repair machinery, including a repair protein called BRCA1.
Also read: Your cholesterol numbers explained: LDL, HDL and the targets you need to know
In the mouse study, treated animals had less DNA damage in their neurons and less inflammation in the brain, according to the King's College London press release on EurekAlert.
The animals are a mouse model of Alzheimer's, so the findings do not yet show the drug works in people.
What Phase 1 completion means in practice
A Phase 1 trial checks whether a drug is safe in healthy volunteers and how the body handles it. It does not test whether the drug works for a disease.
KCL-286 passed that bar during its spinal cord injury development. A future trial in Alzheimer's patients could skip ahead to testing whether it actually helps memory.
Also read: Your sleep position may quietly be affecting your spine, heart and brain
The team now needs funding for a proof-of-concept trial in a small group of Alzheimer's patients.
Professor Jonathan Corcoran, Professor of Neuroscience at King's College London, told Newsweek that a trial of about 20 patients could yield results within a year once funding is in place.
This is still early research. A compound that works in a mouse brain often does not translate to a human brain. Recent years are full of Alzheimer's candidates that looked promising in animals and later failed in people.
Anyone noticing memory changes in themselves or a loved one should talk to a doctor rather than wait for new drugs to arrive. The next step for KCL-286 is a trial in Alzheimer's patients, if the team secures funding.
Also read: What happens to your body, if you eat kimchi every day
Also read: Is red wine actually good for your heart? Here's what science really shows
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.